A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by stimulating the mother’s body’s defences to produce defence proteins, which are then transferred to the foetus through the placenta. This mother-derived protection provides newborns with immediate protection from the point of delivery, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Antibodies from the mother passed through placenta safeguard newborns from day one
- Coverage achievable with 2-week gap before premature birth
- Vaccination in the third trimester still offers meaningful protection for infants
Strong evidence from current research
The effectiveness of the pregnancy RSV vaccine has been demonstrated through a extensive research programme carried out throughout England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing strong and reliable information of the vaccine’s practical effectiveness. The study’s results have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and prospective parents with trust in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This clear distinction highlights the vaccine’s critical role in reducing the risk of serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Study design and parameters
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology captured practical outcomes rather than laboratory-based settings, providing real-world data of how the vaccine works when administered across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the hazards
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces deep inflammation in the lungs and airways, making it extremely challenging for affected infants to feed and breathe properly. Parents frequently observe their babies fighting for breath, their chests rising whilst they try to pull adequate oxygen into their compromised lungs. Whilst the majority of babies get better with palliative treatment, a small but significant group succumb from respiratory syncytial virus complications each year, making prevention through vaccination a vital health service imperative for defending the youngest and most vulnerable people in our communities.
- RSV produces inflammation in lungs, leading to serious respiratory problems in infants
- Half of all infants contract the infection during their first few months alive
- Symptoms span from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies succumb to RSV complications annually in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have highlighted the significance of pregnant women getting their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies via the placenta.
The communication from health authorities remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and availability of the jab. These geographical variations demonstrate variations in medical facilities, engagement approaches, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts deploying varied communication campaigns to connect with pregnant women
- Geographic variations in immunisation take-up in different parts of England require targeted improvement
- Community health services adapting programmes to meet local requirements and situations
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness delivers real advantages for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the launch of this protective measure, the 80% decrease in admissions means thousands of infants spared from severe infection. Parents no more face the distressing scenario of seeing their babies gasping for air or difficulty feeding, symptoms that define critical RSV illness. The vaccine has fundamentally shifted the picture of neonatal lung health, giving expectant mothers a preventative option to shield their youngest infants during those critical early months.
For families like that of Malachi, whose acute RSV infection led to severe brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s support of the jab underscores the transformative consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to women in pregnancy navigating their final trimester, transforming what was once an unavoidable seasonal threat into a controllable health concern.